Triple

T13942290
Position Surface form Disambiguated ID Type / Status
Subject Pfizer–BioNTech E335285 entity
Predicate hasRegulatoryApprovalFor P24602 FINISHED
Object Pfizer–BioNTech COVID‑19 vaccine E812198 NE FINISHED

How this triple was built (3 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Pfizer–BioNTech COVID‑19 vaccine | Statement: [Pfizer–BioNTech, hasRegulatoryApprovalFor, Pfizer–BioNTech COVID‑19 vaccine]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: Pfizer–BioNTech COVID‑19 vaccine
Context triple: [Pfizer–BioNTech, hasRegulatoryApprovalFor, Pfizer–BioNTech COVID‑19 vaccine]
  • A. Vaxzevria COVID-19 vaccine
    Vaxzevria COVID-19 vaccine is a viral vector coronavirus vaccine created to prevent COVID-19 infection and severe disease in adults.
  • B. Janssen COVID-19 Vaccine
    The Janssen COVID-19 Vaccine is a single-dose, viral vector-based coronavirus vaccine developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, for the prevention of COVID-19.
  • C. Pfizer–BioNTech
    Pfizer–BioNTech is a pharmaceutical partnership best known for developing one of the first widely authorized mRNA vaccines against COVID-19.
  • D. Moderna
    Moderna is a biotechnology company best known for pioneering mRNA-based vaccines, including one of the first widely used COVID-19 vaccines.
  • E. BNT162b2 chosen
    BNT162b2 is an mRNA-based COVID-19 vaccine, co-developed by BioNTech and Pfizer, that became one of the first widely authorized vaccines against SARS-CoV-2.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
PD Predicate disambiguation gpt-5-mini-2025-08-07
Target predicate: hasRegulatoryApprovalFor
Context triple: [Pfizer–BioNTech, hasRegulatoryApprovalFor, Pfizer–BioNTech COVID‑19 vaccine]
  • A. hasRegulatoryApproval chosen
    Indicates that an entity has received formal authorization or clearance from a relevant regulatory authority to operate, be sold, or be used in a specified context.
  • B. FDAApprovalType
    Indicates the specific regulatory pathway or category under which a product has been approved by the U.S. Food and Drug Administration.
  • C. regulatoryApprovalYear
    Indicates the calendar year in which an official regulatory body granted approval for the referenced item, action, or entity.
  • D. regulationStatus
    Indicates the regulatory condition or compliance state that applies to an entity under relevant rules or laws.
  • E. hasRegulatedBy
    Indicates that one entity is subject to control, governance, or rules imposed by another entity.
  • F. None of above.

Provenance (4 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69d81c6081b88190b53e317c3370c8fe completed April 9, 2026, 9:38 p.m.
NER Named-entity recognition batch_69de2e0f6f3c8190a64058b732b0ac52 completed April 14, 2026, 12:07 p.m.
NED1 Entity disambiguation (via context triple) batch_69fba1ca49a881909e77b5a2ae13265f completed May 6, 2026, 8:17 p.m.
PD Predicate disambiguation batch_69de05a3ccf88190b45c742db483fa08 completed April 14, 2026, 9:15 a.m.
Created at: April 9, 2026, 10:17 p.m.